A novel dual route vaccination using the Middle East respiratory syndrome coronavirus (MERS-CoV) receptor binding domain sub-unit has been developed.
The US Department of Health and Human Services (HHS) awarded a contract for $535 to Emergent BioSolutions Inc. for Vaccinia Immune Globulin Intravenous (VIGIV) to be used in the Strategic National Stockpile. VIGIV is the only therapeutic licensed by the US Food and Drug Administration (FDA) for the treatment of complications due to smallpox vaccination.
The NanoVax vaccine platform uses a novel oil-in-water emulsion adjuvant that elicits both systemic and mucosal immunity.
Robert Redfield, director of the US Centers for Disease Control and Prevention (CDC), predicted that responders in the Democratic Republic of the Congo will exhaust the current supply of Ebola vaccine before manufacturers can produce more.
The Czech Republic has been the only country to eradicate African swine fever (ASF) during the re-emeging outbreaks around the world in recent years. They eradicated the highly infectious virus through strict control measures, strict biosecurity, and a coordinated approach to both.
One Health is underutilized in the development of vaccines against shared human and animal disease threats.
Southeast Asia is battling to contain the spread of African swine fever, which has so far led to the culling of millions of pigs in China and Vietnam.
There is a great deal of work to do to eliminate cholera from the Global South, but progress is being made.
Researchers observed different functional states of the influenza virus polymerase as it is actively transcribing, providing valuable information for the next generation of anti-influenza drugs.
Researchers demonstrated that targeting a specific portion of the flu virus that varies little from strain to strain offers protection in humans.